Clinical Trials Directory

Trials / Completed

CompletedNCT03982355

Development and Validation of a Tumour Oxygenation Monitoring Probe

Status
Completed
Phase
Study type
Observational
Enrollment
20 (actual)
Sponsor
Imperial College London · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Laboratory based study in which novel tissue oxygenation probe with the potential provide novel means for assessing response to cancer treatment will be developed and validated.

Detailed description

Tumour hypoxia is feature common to most solid tumours, with significant implications in tumour aggressiveness, metastatic potential and response to therapy. Tumour oxygenation monitoring is likely, therefore, to provide a valuable adjunct in risk stratification and treatment response monitoring. Diffuse reflectance spectroscopy (DRS) utilises the differing absorption of oxygenated as compared to deoxygenated haemoglobin to provide an accurate measure of tissue oxygenation. This project aims to develop and validate a tissue oxygenation probe for cancer monitoring. Using the clinical paradigms of rectal and breast cancer, anonymised MRIs of cancer sufferers will guide simulations of tissue optical properties to develop a DRS probe. The 3D reconstructed sans will then be used to 3D print tissue phantom models on which the DRS probe will be validated against reference bench top analysers.

Conditions

Interventions

TypeNameDescription
DEVICEDRS probeThe Oxygenation measurements of the novel diffuse reflectance spectroscopy probe

Timeline

Start date
2019-08-09
Primary completion
2020-06-30
Completion
2020-06-30
First posted
2019-06-11
Last updated
2024-09-19
Results posted
2024-09-19

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03982355. Inclusion in this directory is not an endorsement.